Studying Fentanyl in Patients With Cancer
|ClinicalTrials.gov Identifier: NCT00899951|
Recruitment Status : Terminated (poor accrual)
First Posted : May 12, 2009
Last Update Posted : April 18, 2013
RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at fentanyl in patients with cancer.
|Condition or disease||Intervention/treatment|
|Brain and Central Nervous System Tumors Chronic Myeloproliferative Disorders Leukemia Lymphoma Lymphoproliferative Disorder Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Pain Precancerous Condition Unspecified Adult Solid Tumor, Protocol Specific||Drug: fentanyl citrate Other: pharmacological study|
- To describe the pharmacokinetics of prolonged intravenous infusions of fentanyl citrate in adult patients with cancer.
OUTLINE: Patients undergo blood sample collection before and after discontinuation of fentanyl citrate therapy (10 days total). Pharmacokinetic analysis is performed on the samples.
|Study Type :||Observational|
|Actual Enrollment :||2 participants|
|Official Title:||Pharmacokinetics of Continuous Infusion Fentanyl in Cancer Patients|
|Study Start Date :||October 2007|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||July 2009|
receiving fentaly citrate
|Drug: fentanyl citrate Other: pharmacological study|
- Pharmacokinetics of fentanyl citrate [ Time Frame: two baseline samples, serial samples obtained at 0,4,8,24,48,72,96,168,240 hrs after discontinuing fentanyl ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899951
|United States, Maryland|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Baltimore, Maryland, United States, 21231-2410|
|Principal Investigator:||Stuart A. Grossman, MD||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|